Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 4/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.46 |
| ▸ | FABP2 | P12104 | 2/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4538466 | 0.88 | PPARA (0.65) | PPARACYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL9035478 | 0.81 | ALDH1A1 (0.50) | CYP1A2CYP3A4CYP2C19MAPTTSHR | |
| SCHEMBL9035012 | 0.81 | CA1 (0.47) | CYP1A2MAPTTSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL13802159 | 0.81 | ACHE (0.41) | PPARACYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL1889507 | 0.79 | MEN1 (0.39) | PPARACYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL9165045 | 0.79 | NFE2L2 (0.39) | PPARAMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL9162934 | 0.79 | HSP90AA1 (0.42) | TSHRHTR2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL6210928 | 0.78 | CA4 (0.39) | PPARACYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL25219752 | 0.78 | CA1 (0.44) | PPARAPPARGALDH1A1PPARD | |
| SCHEMBL6212379 | 0.77 | PPARA (0.49) | PPARACYP1A2CYP3A4CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1512397-B1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2014-10-08 | — | — | EP | claimed |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-05-06 | — | — | US | claimed |
| CN-1658855-B | O-substituted hydroxyaryl derivatives | INST MED MOLECULAR DESIGN INC | 2010-04-28 | — | — | CN | claimed |
| US-20050192269-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | THOMPSON RICHARD C (US) | 2005-09-01 | — | — | US | claimed |
| US-20040106598-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting Beta-amyloid peptide release and/or its synthesis by use of such compounds | THOMPSON RICHARD C (US) | 2004-06-03 | — | — | US | claimed |
| EP-1089980-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 2001-04-11 | — | — | EP | claimed |
| WO-1999067221-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1999-12-29 | — | — | WO | claimed |
| US-4060617-A | Esters of the ophyllinylacetic acid | Wulfing, Johann A. (DT) | 1977-11-29 | — | — | US | claimed |
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-23 | — | — | US | disclosed |
| CN-112189008-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-01-05 | — | — | CN | disclosed |
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-19 | — | — | US | disclosed |
| EP-3704094-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-2576507-B1 | HEXAFLUOROISOPROPYL CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2017-04-05 | — | — | EP | disclosed |
| US-RE32581-E | Certain substituted phenyl esters of nicotinic acid, compositions and methods of using same for treatment of hyperlipidemia | MERZ + CO. GMBH & CO. (DE) | 1988-01-19 | — | — | US | disclosed |
| US-4412998-A | ANTILIPEMIC | MERZ & COMPANY (DE) | 1983-11-01 | — | — | US | disclosed |
| US-4321268-A | Certain substituted phenyl esters of nicotinic acid, compositions and methods of using same | MERZ & CO. (DE) | 1982-03-23 | — | — | US | disclosed |
| US-4255444-A | ANTICHOLESTEROL AGENTS | SANKYO COMPANY LIMITED (JP) | 1981-03-10 | — | — | US | disclosed |
| US-4060617-A | Esters of the ophyllinylacetic acid | Wulfing, Johann A. (DT) | 1977-11-29 | — | — | US | disclosed |
| US-4060617-A | Esters of the ophyllinylacetic acid | Wulfing, Johann A. (DT) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | PPARA 2115/4885CYP1A2 2965/4885CYP3A4 3526/4885 |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | PPARA 2115/4885CYP1A2 2965/4885CYP3A4 3526/4885 |
| US-20100113770-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | RELA, NFKBIA, NFE2 | PPARA 130/4885CYP1A2 855/4885CYP3A4 1664/4885 |
| US-20040106598-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting Beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | PPARA 1886/4885CYP1A2 3381/4885CYP3A4 3317/4885 |
| US-20050192269-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | PPARA 1738/4885CYP1A2 3219/4885CYP3A4 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.